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Cholesterol Crystals Induce Coagulation Activation through
Complement-Dependent Expression of Monocytic Tissue
Factor
Caroline S. Gravastrand,*,† Bjørg Steinkjer,*,† Bente Halvorsen,‡,x,{ Anne Landsem,‖,#
Mona Skjelland,** Eva Astrid Jacobsen,†† Trent M. Woodruff,‡‡ John D. Lambris,xx
Tom E. Mollnes,*,‖,#,{{ Ole-Lars Brekke,‖,# Terje Espevik,*,† and Anne Mari A. Rokstad*,†,‖‖
Cholesterol crystals (CC) are strong activators of complement and could potentially be involved in thromboinflammation through
complement–coagulation cross-talk. To explore the coagulation-inducing potential of CC, we performed studies in lepirudin-based
human whole blood and plasma models. In addition, immunohistological examinations of brain thrombi and vulnerable plaque
material from patients with advanced carotid atherosclerosis were performed using polarization filter reflected light microscopy to
identify CC. In whole blood, CC exposure induced a time- and concentration-dependent generation of prothrombin fragment 1+2
(PTF1.2), tissue factor (TF) mRNA synthesis, and monocyte TF expression. Blocking Abs against TF abolished CC-mediated
coagulation, thus indicating involvement of the TF-dependent pathway. Blockade of FXII by corn trypsin inhibitor had a
significant inhibitory effect on CC-induced PTF1.2 in platelet-free plasma, although the overall activation potential was low.
CC exposure did not induce platelet aggregation, TF microparticle induction, or TF on granulocytes or eosinophils. Inhibition
of complement C3 by CP40 (compstatin), C5 by eculizumab, or C5aR1 by PMX53 blocked CC-induced PTF1.2 by 90% and
reduced TF+ monocytes from 18–20 to 1–2%. The physiologic relevance was supported by birefringent CC structures adjacent
to monocytes (CD14), TF, and activated complement iC3b and C5b–9 in a human brain thrombus. Furthermore, monocyte
influx and TF induction in close proximity to CC-rich regions with activated complement were found in a vulnerable plaque. In
conclusion, CC could be active, releasable contributors to thrombosis by inducing monocyte TF secondary to complement
C5aR1 signaling. The Journal of Immunology, 2019, 203: 853–863.
T
he World Health Organization estimates that cardiovascu-
lar disease causes more than 17 million deaths every year.
Of these, 80% are due to myocardial infarction or ischemic
stroke as a result of thrombosis obstructing blood flow to the heart
or brain, respectively (1). Thrombosis occurs following athero-
sclerotic plaque rupture and involves lesion-derived tissue factor
(TF) from endothelial cells (2), plaque macrophages (3, 4), and
blood monocytes following exposure to oxidized LDL and C-reactive
protein (5, 6). Cholesterol crystals (CC) formed upon oxidized LDL
accumulation at the lesion sites are hallmarks of atherosclerotic
plaques (7). Their sharp, needle-like structure promotes erosion
of the fibrous cap and thereby plaque rupture with release into
blood (8). Except for their role in promoting plaque rupture, CC
are considered passive participators in the thrombotic events.
CC activate the complement system (9, 10), whereas their role
as direct promoters of coagulation has not yet been investigated.
The recent finding of CC being strong inducers of complement-
dependent inflammatory processes (11) raises the question of whether
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CC could activate coagulation through thromboinflammation. This
question is further justified in light of evidence of cross-talk be-
tween the complement and coagulation cascades (12–16).
The complement and coagulation cascades are first-line defense
systems mediating inflammation and clot formation, respectively.
Both consist of circulating zymogens converting to reactive prote-
ases upon proteolytic activation (12). Complement can be activated
through the classical, lectin, or alternative pathways, converging in
the formation of C3 convertases. Downstream formation of C5
convertases cleaves C5 and leads to formation of C5a, a highly
potent proinflammatory mediator (17), and the terminal com-
plement complex (TCC) C5b–9. Of note, CC induce activation
of all three complement pathways (18).
The coagulation system is activated either through the intrinsic
pathway, activating FXII to FXIIa on a surface, or through the
extrinsic pathway by binding of FVIIa to cellular expressed TF.
Both pathways converge in the activation of FX to FXa, with
subsequent cleavage of prothrombin to thrombin. This leads to the
conversion of circulating fibrinogen to insoluble fibrin. Together
with activated platelets, this process builds up a stable thrombus.
TF is the major initiator of blood coagulation in vivo and is, under
normal conditions, only expressed on extravascular cells. However,
circulating monocytes are capable of expressing TF on their surface
when exposed to proinflammatory stimuli, including LPS, TNF,
C-reactive protein, and C5a (19). The latter demonstrates one of
the most important points of cross-talk between the complement
and coagulation systems (12).
Activated factors of complement and coagulation are evident within
aspirates of human atherosclerotic plaques and thrombi. More spe-
cifically, TCC as well as mRNA of complement C1r, C1s, and C4 are
found within atherosclerotic lesions (20). C3 has been detected in
thrombi (21), and C3a and C5a have been shown to be increased
in surrounding plasma at the site of thrombus formation (22). This
suggests local complement activation within the plaque and thrombi.
Leukocyte-associated TF has also been found in thrombi and is
thought to contribute to clot propagation and growth (23).
Because CC activate complement, and there is an increased
recognition of complement–coagulation cross-talk, the aim of the
current study was to investigate the role of CC in thrombosis by
studying their activation of coagulation and the dependency of
complement activation in this process.
Materials and Methods
Reagents
This work includes the following reagents: anticoagulant lepirudin
(Refludan) from Celgene Europe (Boudry, Switzerland) and sterile PBS
(PBS with or without Ca2+ and Mg2+) and EDTA from Sigma-Aldrich
(St. Louis, MO). Human serum albumin (HSA) was from Octapharma
(Jessheim, Norway). Heat-inactivated Escherichia coli strain LE392
(ATCC 33572) was from the American Type Culture Collection (Manassas,
VA). CryoTubes (polypropylene) were from Nunc (Roskilde, Denmark).
Complement inhibitors were as follows: compstatin analog CP40 (sequence:
14-aa cyclic peptide [D]Tyr-Ile-[Cys-Val-Trp(Me)-Gln-Asp-Trp-Sar-Ala-
His-Arg-Cys]-mIle-NH2) and a control peptide (Sar-Sar-Trp(Me)-Ala-Ala-
Asp-Ile-His-Val-Gln-Arg-mlle-Trp-Ala-NH2), synthesized as described (24);
C5 inhibitor eculizumab (Soliris) from Alexion Pharmaceuticals (New Haven,
CT) and control rituximab (Roche, Basel, Switzerland); and cyclic peptide
C5aR1 antagonist PMX53 (AcPhe-[Orn-ProdCha-Trp-Arg]), synthesized as
described (25). TF inhibitors used included the functional grade purified in-
hibitory Ab against human TF (HTF-1) from eBioscience (San Diego, CA)
and Ultra-LEAF Purified Mouse IgG1k (MG1-45, 400165) from BioLegend
(San Diego, CA). Corn trypsin inhibitor (CTI; CTI-01) from Haematologic
Technologies (Essex Junction, VT) was used as a factor XII inhibitor. Flow
cytometry Abs included anti-CD14 FITC (MFP9) from BD Biosciences
(345784), anti–HLA-DR allophycocyanin–Cy7 (L243) from BioLegend
(307602), anti–Siglec-8 allophycocyanin (7C9) from BioLegend (347106),
anti-TF PE (CD142, NY2) from BioLegend (365204), and anti-mouse
IgG1, k PE (MOPC-21) BioLegend (981804). FACS Lysing Solution
was from BD Biosciences. Abs for histology included murine monoclonal
neoepitope anti-human C9 (DIA011-01, clone E11, isotype IgG2a) from
BioPorto Diagnostics (DK-2820; Gentofte, Denmark), neoepitope anti-human
iC3b (A209, isotype IgG1) from Quidel (San Diego, CA), mAb against human
TF (CD142, ADG4509, clone IIID8, isotype IgG1) from Sekisui (American
Diagnostica, Pfungstdt, Germany), a monoclonal anti-human CD14 (18D11,
isotype IgG1) synthesized in-house, monoclonal mouse anti-human CD68
(clone KP1, M0814, isotype IgG1), and anti-human CD61 (clone Y2/51,
M0753, isotype IgG1) from Dako (Glostrup, Denmark). Isotype controls
were purified mouse Igs IgG1 (clone MOPC-21), IgG2a (clone MOPC-172),
and IgG2b (clone MPC-11) from BioLegend.
Preparation of CC and endotoxin measurement
CC were prepared as described by Samstad et al. (10). Briefly, ultrapure
cholesterol (100 mg) was dissolved in 1-propanol (50 ml and aggregated
by the addition of distilled water. CC were air-dried and suspended in
0.05% (w/v) HSA/PBS. After preparation, the endotoxin contamination
was measured in a Chromogenic LAL Assay (Lonza). The LPS was below
the detection limit (0.1 endotoxin units/ml) in a sample size of 50 mg/ml
CC, and thus, the endotoxin content would be below 0.18 pg/mg CC.
Experiments in human whole blood
Human whole blood from healthy volunteers, anticoagulated with lepirudin
(50 mg/ml), was used as first described by Mollnes et al. (26). Final
concentrations of CC or controls were as follows: CC (500, 1000, and 2000
mg/ml), E. coli (13 107 particles/ml), or glass control (200 ml of PBS with
Ca2+/Mg2+ in BD Vacutainer glass tubes). Final concentrations of inhibi-
tors were as follows: CP40 or its peptide control (20 mM), eculizumab and
its Ab control (100 mg/ml), anti-TF (10 mg/ml) or control Ig (10 mg/ml),
and PMX53 (10 mM). The incubation time was between 60 and 240 min,
as stated for the individual experiments. Complement and coagulation
activity was terminated by addition of EDTA (10 mM final concentration).
Whole blood was retracted for flow cytometric analysis. Plasma was
harvested after centrifugation at 20003 g for 15 min and stored in aliquots
at 220˚C for analyses of prothrombin fragment 1+2 (PTF1.2). After
plasma harvesting, the pellets were added to 350 ml of PBS (equal to
plasma harvesting) and further processed as described in TF mRNA below.
Experiments in platelet-free plasma
Platelet-free plasma (PFP) anticoagulated with lepirudin (50 mg/ml) was
made by centrifugation at 2500 3 g for 15 min twice at room temperature
(RT). Each time the upper plasma fraction was retained while discarding the
lowest 0.5 ml of rich fraction with platelets. The fresh plasma was incubated
with or without CTI at a final concentration of 40 mg/ml in the presence of
CC (2000 mg/ml) or in glass vials with incubation lengths of 60 and 240 min.
PTF1.2 quantification
PTF1.2 levels were quantified in duplicate using the Enzygnost Prothrombin
F1+2 ELISA kit (Monoclonal OPBD03; Siemens Healthcare, Marburg,
Germany) following the manufacturer’s instructions. ODwas measured using
a PolarStar OMEGA plate reader (BMG Labtech, Ortenberg, Germany).
TF mRNA
Cell pellets (550 ml) were added to 1.53 ml of PaxGene Blood RNA tubes
solution (PreAnalytiX, Hombrechtikon, Switzerland) and stored at 280˚C
until RNA extraction. Total RNA was extracted using the MagNA Pure 96
Cellular RNA large volume kit (Roche Diagnostics, Mannheim, Germany)
according to the manufacturer’s instructions, and the concentration was
measured using the NanoDrop 2000c spectrophotometer (Thermo Fisher
Scientific, Wilmington, DE). cDNA was synthesized using the High-
Capacity cDNA Reverse Transcription Kit and 2720 Thermal Cycler (Ap-
plied Biosystems, Foster City, CA) and stored at 280˚C. TF mRNA levels
were measured using the StepOne Plus Real-Time PCR System (Applied
Biosystems). Gene expression was detected by TaqMan Fast Universal PCR
Master Mix reagents and predeveloped TaqMan gene expression assays
using the target gene TF (TF, Hs 0017225) with reference gene human b-2-
microglobulin (TaqMan B2M Probe Dye FAM, 4333766–0804015) analyzed
using quantitative PCR with cycle conditions according to the manual.
TF-bearing microparticle quantification
TF-bearing microparticles (TF-MP) with procoagulant activity were
quantified using Aniara ZYMUPHEN MP-TF (521196; Hyphen BioMed,
Neuville Sur Oise, France) according to the producer’s protocol. Before-
hand, whole blood samples were added to sodium citrate 3.2% (from
Vacuette blood collection tubes; Greiner Bio-One) in 1:10 dilution and
















thereafter centrifuged at 1500 3 g 15 min at RT before the plasma frac-
tions were further centrifuged at 13,0003 g for 2 min at RT. PFP was then
harvested by retracting 400 ml from the uppermost plasma fraction.
Samples were stored at 280˚C until analysis.
Flow cytometry
EDTA-inactivated blood samples (50 ml) were added to a mixture of anti-
CD14 FITC (2.5 ml), anti–Siglec-8 allophycocyanin (1.25 ml), anti–HLA-
DR allophycocyanin–Cy7 (1.25 ml), and anti-TF PE (IgG1; 1.25 ml) or
isotype control (0.625 ml, concentration-matched) for anti-TF (anti-mouse
IgG1k PE), and RBCs were lysed by 1 ml of FACS Lysing Solution
(diluted 1:10 in H2O). Samples were analyzed using a BD FACSCanto II
flow cytometer with data processing in FlowJo software (version 10;
Tree Star). To separate the monocytes from granulocytes and eosinophils
emitting autofluorescence following CC exposure, a flow cytometric gating
strategy based on the following settings was used: monocytes defined by
side scatter (SSC)+(medium)/CD14+(high)/Siglec-82/MHC class II (MHCII)+,
granulocytes by SSC+(high)/CD14+(low)/Siglec-82/ MHCII2, and eosino-
phils by SSC+(high)/Siglec-8+/MHCII2. The percentages of TF+ leukocytes
were determined in a histogram plot set by the control Ab. The gating
strategy is given in Fig. 1.
Platelet aggregation assay
Platelet aggregation was analyzed on a Multiplate electrical impedance
aggregometry analyzer (Roche). Blood was collected in 4.5-ml plastic
blood collection tubes containing the anticoagulant hirudin (25 mg/ml;
Roche). After a 30-min rest at 20˚C, the samples were diluted with 5%
(v/v) PBS without Ca2+ and Mg2+ with 0.05% (w/v) HSA (Octapharma) or
CC (500–2000 mg/ml). The samples were analyzed as recommended by
the manufacturer, adding 0.3 ml of preheated (37˚C) isotonic saline (0.9%)
to 0.3 ml of whole blood in the Multiplate test cell, followed by incubation
for 3 min at 37˚C. The aggregation response over 6 min was expressed by
the area under the curve as arbitrary units 3 min, either by the CC or its
background control alone or following additional stimulation with 20 ml of
ADP or thrombin receptor activating peptide-6 (TRAP) test as described
by the producer (Roche).
Human thrombus and plaque material
Intracranial thrombus material was obtained by arterial recanalization or
thrombectomy (27) from a single-center cohort study (28). Carotid plaques
were obtained by carotid endarterectomy. Study inclusion criteria
were acute stroke with clinical ischemic symptoms corresponding to an
angiographically proven large intracranial vessel occlusion, absence of
intracranial hemorrhage on computed tomography scan, and a clearly
defined time of symptom onset within 6 h of inclusion. Mechanical
thrombectomy involved arterial catheterization from the groin artery to the
level of the intracranial vessel occlusion and thrombus retraction with the
use of a retrievable stent delivered through a microcatheter. After retrac-
tion, the thrombi were stored at 4˚C in Allprotect tissue reagent (Qiagen)
or snap-frozen.
Histology
Histology processing was performed at the Cellular and Molecular Imaging
Core Facility Histology laboratory at Norwegian University of Science and
Technology. We chose frozen tissue material without preservations because
of the possibility of preserving neoepitopes of activated complement and
preserving the CC structures. Briefly, frozen thrombi tissue sections (4 mm)
were stained for hematoxylin erythrosine saffron (HES) or with specific
Abs. The HES procedure, in brief, was as follows: rehydration through
descending grades of ethanol to water (1 min), staining in aqueous he-
matoxylin (5 min) followed by bluing in water (8 min), erythrosine
treatment (5 min) and rinsing in water (1 min), dehydrating in ethanol
(80, 96, and 100%), and staining in saffron (5 min) before rinsing in ab-
solute ethanol and clearing in Tissue Clear. Cover-slipping used Sakura
FIGURE 1. Flow cytometric gating strategy for separating monocytes from granulocytes and eosinophils. (A) Nonstimulated blood. Monocytes were
easily distinguished as the SSC+(medium)/CD14+(high), Siglec-82, and MHCII+ population (red color in fourth picture). (B) CC-stimulated blood. Monocyte
and eosinophil populations merged in the CD14+/SSC+ plot; thus, a large gate was set to include the most granular monocytes. Thereafter, monocytes were
selected by a negative selection of the Siglec-82 population (based on settings from nonstimulated blood) and a positive selection of the MHCII+ cells (red
color, second and third pictures), resulting in a distinguished monocyte population (red color in fourth picture). (C) E. coli–stimulated blood. Monocytes and
granulocytes were separated, and the monocytes were distinguished further by Siglec-82 and MHCII+ staining. The percentage of TF+ cells was determined
by a histogram plot of fluorescence intensity, determining baseline setting from nonstimulated blood, and the isotype control was subtracted from the
positive staining obtained from the specific TF Ab. The granulocytes and eosinophils were further distinguished by negative and positive selection,
respectively, of Siglec-8–stained cells (data not shown) and further analyzed for TF expression.
















Tissue-Tek Glas. Specific Ab staining, in brief, was as follows: frozen
sections on SuperFrost Plus slides were dried (10 min) and washed
(soaking in Dako S3006 buffer), quenched for endogenous peroxidase
activity in Peroxidase Block (Dako K4011), and treated with Protein Block
Serum-Free (Dako X0909) for 20 min. The primary Abs were incubated
overnight at 4˚C by the following dilutions: anti-C9 (IgG2a, 1 mg/ml)
neoepitope in 1:10,000 (plaque) and 1:5000 (thrombi) dilutions, anti-
iC3b neoepitope (IgG2b, 1.04 mg/ml) in 1:1500 dilution, anti-TF (IgG1,
0.5 mg/ml) in 1:1000 dilution, anti-CD14 (IgG1, 165 mg/ml) in 1:200
dilution, anti-CD68 (IgG1, 156 mg/l) in 1:5000 dilution, and anti-CD61
(IgG1, 647 mg/l) in 1:5000 dilution. Negative controls were isotype- and
concentration-matched. Finally, washing buffer was added followed by
30 min in labeled polymer HRP anti-mouse (Dako K4011), rinsing, and
incubation in DAB (Dako K4011). Counterstaining was by a nonalcoholic
aqueous hematoxylin (2 min) and mounting medium. Images were taken
by an inverted fluorescence microscope (Olympus IX71) using a polari-
zation filter and an Olympus XC30 CCD color camera and 43–403 ob-
jectives, processed with Cell^P image visualization software, and optimized
in Adobe Illustrator version 10.0.1 using linear stretch adjustments.
Statistical analysis
GraphPad Prism software (version 7.0a) was used for statistical analyses.
Two-way ANOVA with multiple comparisons was used to evaluate the
effects between stimuli, controls, and inhibitors. The Dunnett multiple
comparisons test was used for the time course studies, the Tukey multiple
comparisons test was used when comparing each condition of CC with its
inhibitor and inhibitor control, and the Sidak multiple comparisons test was
for additional data comparing each CC condition with inhibitor. The data
generated by continuous scales were log-transformed beforehand to ensure
normal distribution. A Wilcoxon matched-pairs signed-rank test was used
for comparisons between two conditions.
Ethical approval
The use of human whole blood was approved and followed the guidelines as
recommended by the Regional Committees for Medical and Health Re-
search Ethics under Research Ethics Committee Central (REK 2009/2245)
and in accordance with the Helsinki Declaration. The use of thrombi and
plaque material was approved by the South East Norway Research Ethics
Committee (REK 2014/2078), and written informed consent was obtained
from all patients.
Results
CC induce PTF1.2 in human lepirudin whole blood
Lepirudin specifically inhibits thrombin and thus avoids fibrinogen
activation and downstream coagulation while still allowing the
coagulation system to be activated upstream. Despite the inhibition
of the thrombin feedback loop, the upstream coagulation proteins
together with all complement proteins are able to be activated,
thereby allowing interaction with leukocytes. The conversion of
prothrombin to thrombin results in a cleavage product, PTF1.2,
that serves as an indirect estimate of the initial coagulation acti-
vation by either of the two coagulation pathways. CC 2000 mg/ml
induced a significant increase (p , 0.001) of PTF1.2 compared
with the PBS/HSA control following 240 min of incubation
(Fig. 2A). Significant elevation was achieved for CC 1000 mg/ml
(p , 0.05), whereas a nonsignificant (p . 0.05) elevation was
obtained under exposure to CC 500 mg/ml (data not shown). Glass
significantly elevated PTF1.2 levels by 60 min (p , 0.0001) and
E. coli by 120 min (p , 0.001) (Fig. 2A). Glass is a highly potent
activator of coagulation FXII and can be inhibited by CTI (29),
whereas E. coli activates TF that can be explored by TF-inhibiting
Abs (14). Inhibiting TF prior to addition of CC using a TF-
blocking Ab efficiently and significantly (p , 0.0001) blocked
the CC- and E. coli–induced PTF1.2 (Fig. 2B). These data pointed
to the TF-driven pathway as most important for the CC-induced
PTF1.2. To test for the FXII dependency, CC or glass were in-
cubated in lepirudin PFP with or without blockage of FXII using
CTI. In PFP, the overall PTF1.2 induction by CC or glass was low
(just above baseline) but could still be significantly (p , 0.05)
inhibited by CTI (Fig. 2C). The ability of CC to induce platelet
FIGURE 2. CC induce PTF1.2 dependent on
the TF pathway. (A) PTF1.2 induction over time
(60, 120, and 240 min) upon exposure to CC
2000 mg/ml, PBS/HSA, E. coli (1 3 107 parti-
cles/ml), or glass (n = 7 donors) in human whole
blood. (B) Effect of TF inhibition following ex-
posure of CC (500, 1000, and 2000 mg/ml) or
E.coli after addition of the functional-grade in-
hibitory Ab against TF (anti-TF) or the corre-
sponding Ultra-LEAF purified IgG1k control Ab
(Ctr IgG) for 240 min in human whole blood
(n = 6 donors). (C) Effect of factor XII inhibition
by CTI (40 mg/ml) in PFP following incubation
with CC (2000 mg/ml) or glass for 60 min
(n = 5). Effect of CC on platelet aggregation in
human whole blood measured by electrical im-
pedance aggregometry in (D) by CC (2000 mg/ml)
or its controls, HSA/PBS, or TRAP (n = 6), (E) by
additional stimulation with ADP (n = 3), and in (F)
with TRAP following 6 min of incubation (n = 3),
given as arbitrary units 3 min. In all experiments,
thrombin was inhibited with lepirudin. All data are
given as means 6 SEM. *p , 0.05, **p , 0.01,
***p , 0.001, ****p , 0.0001.
















aggregation was investigated by electrical impedance aggreg-
ometry (Fig. 2D–F). CC did not induce platelet aggregation as
compared with its background control (HSA/PBS) and positive
control, TRAP (Fig. 2D). The CC did not induce additional acti-
vation or inhibition in activated platelets, as investigated by the
ADP test (Fig. 2E) or the TRAP test (Fig. 2F). Altogether, these
data point to the TF pathway as the main pathway triggered by
CC, with a small contribution from FXII.
CC induce coagulation through monocytic TF
The procoagulant activity of TF detected in the inhibition studies
(Fig. 2B) could be a consequence of cellular expressed TF or
TF-MP. Measuring TF at the transcriptional level (TF mRNA)
after CC 2000 mg/ml exposure in the whole blood resulted in a
highly significant (p , 0.0001) increase as compared with the
PBS/HSA control, peaking after 60 min of incubation (Fig. 3A).
Similar patterns, although less prominent, were found following
exposure of CC 1000 mg/ml and CC 500 mg/ml (Supplemental
Table I). In comparison, E. coli induced a significant (p , 0.0001)
and stronger response but also peaking after 60 min (Fig. 3A).
Measuring the TF-MP activity in human whole blood (Fig. 3B)
resulted in the lack of activity following CC exposure, although
the E. coli induction was consistent with previous data (14).
We further investigated the TF expression on the surface of
the monocyte and granulocyte populations using flow cytometry.
The monocytic population (CD14+/Siglec-82/MHCII+) histogram
showed a clear shift to the right for TF following CC exposure
(Fig. 3C) and stronger for E. coli. Quantification from six donors
indicated an average of 23% of the monocytic population
expressing TF at the surface upon CC 2000 mg/ml exposure and
between 18 and 20% at the lower concentrations (Supplemental
Table II). Of note, a significant increase was detected already
after 60 min for CC 2000 mg/ml (p , 0.001) and CC 1000 mg/ml
(p , 0.05) and after 120 and 240 min for all concentrations of
CC (Supplemental Table II). E. coli induced the fastest and
strongest TF expression, involving between 70 and 80% of the
monocyte population, in agreement with previous findings. In
contrast, no shift in TF was found on the surface of the granulocytes
(SSChigh/CD142/Siglec-82) for either CC or E. coli stimulation
(Fig. 3D) (14). Equally, no TF induction could be detected on the
eosinophilic population (SSChigh/MHCII2/Siglec-8+; data not
shown). In conclusion, CC induces synthesis of TF mRNA,
whereas only monocytes express TF at the surface.
CC induce coagulation through an initial
complement activation
CC are strong activators of complement, leading to TCC formation
(10). Complement-induced TF has previously been demonstrated
(13–15), suggesting a possibility also for CC-induced coagulation.
Inhibiting complement by blocking C3 (CP40) or C5 (eculizumab)
significantly (p , 0.0001) reduced the CC-induced PTF1.2 and
monocyte TF expression close to baseline (Fig. 4A–D). Of note,
FIGURE 3. CC induce TF mRNA and TF expres-
sion on the monocyte surface. Human whole blood
was incubated with CC (500, 1000, and 2000 mg/ml) or
controls, PBS/has, or E. coli (1 3 107 particles/ml) at
different time points (60, 120, and 240 min). (A) TF
mRNA in whole blood measured by quantitative
RT-PCR (n = 6 donors); additionally, CC 1000 and
500 mg/ml are in Supplemental Table II. (B) The
procoagulant activity of TF-MP (n = 3 donors). (C)
Monocyte TF expression exemplified with flow
cytometry histogram after 120 min and quantified as
percentage of monocytes expressing surface TF at all
time points (n = 6 donors). Additionally, CC 1000 and
500 mg/ml are shown in Supplemental Table II. (D)
The lack of granulocyte TF expression exemplified
with flow cytometry histogram after 120 min and
quantified as percentage of granulocytes expressing
surface TF at all time points (n = 6 donors). Histogram
baselines (T0) are stippled lines, isotype controls are
filled gray, and the TF expression are black lines.
Graphs are given as means 6 SEM. Significant differ-
ences between the stimuli and inhibitors at the given
time points are marked with asterisks. **p , 0.01,
***p , 0.001, ****p , 0.0001.
















the percentage of monocytes expressing TF was ,1% upon in-
hibition of C3 and ,2% upon inhibition of C5. Upon E. coli
exposure, the inhibition was less efficient, in accordance with
previous data demonstrating the need for dual blockage of CD14
and complement C5 to avoid E. coli–induced coagulation (14).
Because the inhibition of CC was efficient also at the level of C5,
we further investigated the involvement of the anaphylatoxin C5a
receptor, C5aR1, using the inhibitor PMX53. The effective
blocking of the CC-induced PTF1.2 and monocyte TF by PMX53
points to an important role of the C5a–C5aR1 axis in the CC-
induced coagulation (Fig. 4E, 4F). In comparison, blocking of
E. coli–induced PTF1.2 and monocytic TF by PMX53 was less
effective (Fig. 4E, 4F). In conclusion, the CC-induced coagulation
activation measured by PTF1.2 and monocytic TF is dependent on
initial complement activation, in which the anaphylatoxin receptor
C5aR1 is central.
CC are found within human intracranial vessel thrombus
material and are associated with activated complement,
monocytes, and TF+ leukocytes
Our studies in whole blood pointed to complement and monocytes
as essential participators in CC-induced coagulation. To further
explore the physiological relevance of these findings, we next
explored thrombusmaterial retracted from the intracranial vessel of
patients with advanced carotid atherosclerosis. First, we investi-
gated the possibility of detecting CC structures within the thrombus
material and next in the association with complement and mono-
cytes. Because CC are one of few materials showing birefringence in
human tissue (30), it was possible to detect CC structures by
polarization filter reflected light microscopy. Birefringent struc-
tures similar to CC were detected within hematoxylin-stained
samples (Fig. 5A, 5B). In the corresponding HES sections, the
birefringent structures were absent (Fig. 5C, 5D). Crystalized
cholesterol dissolves in ethanol (31), which is one of the con-
stituents of HES. The disappearance of birefringent structures
upon HES staining suggested that the structures could be of
cholesterol origin.
Of note, the CC areas were richly populated with cells having
bean-shaped nuclei typical for monocytes (Fig. 5). Immunohis-
tochemistry staining confirmed the presence of monocytes within
the CC-rich areas, as marked by yellow arrows (Fig. 6A, 6B).
The corresponding adjacent section stained prominently for TF
(Fig. 6C, middle picture). Furthermore, complement neoepitopes
C5b–9 (Fig. 5D) were densely present and strongly associated
with the birefringent CC structures (yellow arrows). The neo-
epitope iC3b was also found within the CC-rich areas (Fig. 5E),
in addition to being present in the outermost regions of the
thrombus (Fig. 5E, left picture, blue arrows). The presence of
monocytes/macrophages in the thrombus was further confirmed
by positive staining for CD68 in areas rich in CC (Supplemental
Fig. 1A). Platelets (CD61), in contrast, were present throughout
the thrombus (Supplemental Fig. 1B). The Ab specificities were
manifested by the areas free of staining and further confirmed
by the lack of staining by their respective isotype control, IgG1
(Supplemental Fig. 1C), IgG2a, and IgG2b (data not shown). In
conclusion, the histological examinations pointed to a physiological
FIGURE 4. CC induce coagulation acti-
vation dependent on an initial complement
activation. Whole blood was incubated with
CC (500, 1000, or 2000 mg/ml), PBS/HSA,
or E. coli (1 3 107 particles/ml) for
240 min with the C3 inhibitor CP40, the
C5 inhibitor eculizumab, or their respective
controls (scrambled peptide for CP40 or
rituximab as control for eculizumab). (A)
PTF1.2 production following C3 inhibition
(CP40; n = 7 donors). (B) Monocyte TF ex-
pression at 120 min of incubation following C3
inhibition (n = 6 donors). (C) PTF1.2 produc-
tion following complement C5 inhibition
(eculizumab; n = 7 donors). (D) Monocyte
TF expression at 120 min of incubation
following C5 inhibition (n = 6 donors). (E)
PTF1.2 following inhibition of complement
receptor C5aR1 with PMX53 after 240 min
(n = 5 donors). (F) Monocyte TF expression
after 120 min of incubation following in-
hibition of C5aR1 with PMX53 (n = 5
donors). Data are given as means 6 SEM.
*p , 0.05, **p , 0.01, ***p , 0.001,
****p , 0.0001.
















relevance of CC and complement in thrombosis through the ac-
tivation of monocytic TF.
Monocyte TF/CD14 expression patterns are connected to CC
and activated complement in vulnerable plaque and in
whole blood
Vulnerable plaques were examined for ruptures, the presence of
CC, complement, and monocytes. One sample showed signs of an
open lumen and had large CC present near the adventitia (Fig. 7A,
Supplemental Fig. 2). Briefly, within the open lumen bright
staining with the monocyte marker CD14 (CD14bright) suggested
monocyte influx and blood exposure (Fig. 7A, yellow arrows). In
the innermost region of the lumen, a layer of CD14low-staining
monocytes was detected (Fig. 7A, first picture, blue arrows). The
corresponding layer stained positive for TF (second picture, blue
arrows). Of note, bright CC structures were observed in the
FIGURE 5. Histology from frozen sections of hu-
man intracranial thrombus retracted from a patient with
advanced carotid atherosclerosis and explored by po-
larization filter reflected light microscopy. (A and B)
Hematoxylin-stained sections with easily identifiable
birefringent CC marked with orange arrows. (C and D)
HES-stained sections of corresponding areas. Corre-
sponding areas are (A) and (D), and (B) and (C). The
thicknesses of the sections are 4 mm. Images were
taken with original magnification 340 objective by a
polarization filter to visualize birefringent structures.
Scale bar, 30 mm.
FIGURE 6. Immunohistochemistry of frozen sec-
tions of human intracranial thrombus retracted from a
patient with advanced carotid atherosclerosis and
explored with polarization filter reflected light mi-
croscopy. (A and B) Staining against the monocyte
marker CD14. (C) Staining against TF. (D) Staining
against the complement neoepitopes C5b–9. (E)
Staining against the complement neoepitope iC3b.
The thicknesses of the sections are 4 mm. Pictures in
the left column are taken by original magnification 34
objective, and the CC-rich area (blue frame) is further
augmented with an original magnification340 objective
(middle and right columns). Examples of birefringent
structures are shown by yellow arrows, whereas blue
arrows point to the outer thrombi sections stained
heavily for neoepitope iC3b. Scale bars, 200 mm for
pictures in left column and 30 mm for pictures in
middle and right columns.
















adjacent region (marked CC). The CC-rich areas stained heavily
for complement iC3b and C5b–9 (Fig. 7A, third and fourth pic-
tures). The monocytic origin of the TF+ cells was further con-
firmed by positive staining for the monocyte/macrophage marker
CD68 and negative staining for CD34 and CD61 in corresponding
areas (Supplemental Fig. 2A). Larger magnifications confirmed
the monocytes’ origin by the presence of bean-shaped nuclei
(Supplemental Fig. 2B) both for the CD14bright and the CD14low/TF+
areas (Supplemental Fig. 2C, 2D). The presence of CC in the area
adjacent to the CD14low/TF+ cells is clearly shown (Supplemental
Fig. 2C–E). Endothelial staining was only found in the area of
CD14bright monocytes, with irregular staining patterns typical
for endothelial renewing (Supplemental Fig. 2E). The Ab speci-
ficities were confirmed by negative controls (data not shown).
The findings of CD14low/TF+-expressing leukocytes within the
plaque could be explained by further observations in whole blood
upon CC exposure (Fig. 7B–H). Briefly explained, in the mono-
cytes, a reduction of CD14 from the initial expression level over
time was observed, with a significant lowering for CC 2000 mg/ml
after 120 and 240 min (p, 0.001–0.0001) and for CC 1000 mg/ml
after 240 min (p , 0.01) (Fig. 7B). Moreover, a negative corre-
lation (r = 20.697) between CD14 expression and the TF+
monocytes (percentage) was identified (Fig. 7C). The CC expo-
sure led to a substantial and significant (p , 0.0001) increase
in the granularity, indicating phagocytosis (10) (Fig. 7D). The
reduction in CD14 (Fig. 7E, 7F) and increase in granularity
(Fig. 7G, 7H) could be inhibited by blocking complement at the
level of C3 and C5, thus linking both events to complement. From
these findings, we would suggest that CC in a vulnerable plaque
situation activates complement, with a subsequent influx of
monocytes, phagocytosis of CC, and induction of TF in mono-
cytes. During this process, CD14 is internalized, in part through
complement-mediated activity.
Discussion
CC have emerged as important contributors to atherosclerotic
inflammation (11), but their potential role in thrombosis is unex-
plored. In this study, we show that CC induce coagulation through
a complement-dependent expression of TF in monocytes by using
an experimental whole blood model. The physiological relevance
FIGURE 7. Human vulnerable plaque and whole blood show corresponding patterns in monocyte TF/CD14 expression and complement activation to CC.
(A) Immunohistochemistry of the vulnerable plaque with the monocyte marker CD14, TF, and activated complement neoepitope iC3b and neoepitopes
C5b–9. Staining areas for CD14bright monocytes are marked with yellow arrows, and CD14low/TF+-expressing monocytes are marked by blue arrows;
specified also are the CC-rich areas, lumen, and adventitia. Sections are 4 mm and are taken by original magnification 34 objective and given for two
adjacent areas in each staining. Scale bar, 200 mm. Whole blood following CC exposure showing effects on (B) monocyte CD14 expression, (C) correlation
between CD14 and TF in monocytes, (D) the increase in monocyte granularity, (E) monocyte CD14 following inhibition of complement C3 (120 min), (F)
monocyte CD14 following inhibition of complement C5 (120 min), (G) monocyte granularity following inhibition of C3 (120 min), and (H) monocyte
granularity following inhibition of C5 (120 min). Data are given as mean fluorescence intensity (MFI; mean6 SEM, n = 6 donors). *p, 0.05, **p , 0.01,
***p , 0.001, ****p , 0.0001.
















of these findings is supported by human intracranial vessel
thrombus and vulnerable plaque histology demonstrating CC in
association with monocyte TF (CD14/TF+ leukocytes) and acti-
vated complement (iC3b and C5b–9). The present data thus point
to an active role of CC and complement in thrombosis.
Atherosclerotic plaques can contain dense amounts of CC (32),
suggesting relatively high concentrations of CC at the releasing
site. In this study, we show that CC in concentrations of 500–2000
mg/ml induce coagulation by cleavage product PTF1.2, mediated
mainly through the TF pathway and TF surface expression by
monocytes. Our data indicate a time span of CC-induced TF ex-
pression of 1–2 h, with TF mRNA peaking after 1 h and full
surface expression after 2 h. Although endothelial damage could
induce a faster response in concert with platelets, these findings
point to releasable CC as active contributors in thrombus forma-
tion and growth. The demonstration of monocyte influx and
TF-expressing monocytes in a vulnerable human plaque further
support monocytes as important effectors in thrombosis. The time
frame from plaque debris release to clinical symptoms is not well
defined and depends on thrombus size and localization. According
to clinical guidelines (33), patients with advanced carotid ath-
erosclerosis should undergo carotid endarterectomy preferably
within 48 h after a transient ischemic attack because of the high
risk of recurrent infarction. The clinical picture with small is-
chemic occlusions such as transient ischemic attack promotes a
high-risk period for up to 2 mo, in which patients are particularly
vulnerable to new and often larger attacks. The release of CC
during this period could thus promote thrombosis by inducing
TF expression on monocytes.
Cholesterol embolization syndrome is a phenomenon charac-
terized by a multitude of small emboli occurring over time in
association with CC, with an incidence of 22–27% during surgical
treatment of atherosclerosis (34). Of note, this phenomenon was
connected to complement consumption, which fits well with the
complement-dependent CC-induced coagulation activation dem-
onstrated in this study. Our data might contribute to a mechanistic
explanation by demonstrating that the coagulation activation is
mediated predominantly by complement, with more than 90%
inhibition at either the level of C3 or C5. The efficient prevention
of coagulation by inhibiting the anaphylatoxin receptor C5aR1
points to an essential role of the C5a–C5aR1 signaling axis in CC-
induced coagulation. This clear effect was in contrast to the partial
inhibition of coagulation by C5aR1 under exposure to E. coli and
clearly points to a specific complement-mediated activation by
CC. Bacteria-induced coagulation is, in addition to complement,
also dependent on CD14 (26) and, furthermore, connected to the
TLR pathway (35). The lack of direct activation of CD14/TLRs by
CC might explain the lower potency of CC to induce TF mRNA,
the lower number of TF+ monocytes, and the lack of TF-MP ac-
tivity presently demonstrated. We observed, however, a rapid loss
of CD14 in correlation with TF induction following CC exposure.
This phenomenon was concentration-dependent and linked to
complement and could possibly be the consequence of phagocy-
tosis of CC. Whether CD14 is involved in the signal induction
leading to TF expression remains to be elucidated. Previous ex-
ploration by our group has shown that the CC-induced comple-
ment activation mediates upregulation of CR3 (CD11b/CD18)
through C5a/C5aR1 (10). The additional opsonization with com-
plement fragments at the level of C3 leads to efficient phagocy-
tosis of CC. This was also demonstrated in the current study by the
concentration-dependent granulation in monocytes after CC ex-
posure, which could be blocked by the complement inhibitors both
at the level of C3 and C5. Although we did not explore the link
between monocyte TF and the phagocytic events, the rapid
phagocytosis prior to TF mRNA synthesis, as well as the com-
plement dependency for both, could indicate that these events
are connected.
The inflammatory cytokines TNF and IL-1b, among others, are
triggered by CC exposure (10). The induction of TF has also been
connected to TNF (36), which could suggest its involvement in
CC-mediated coagulation. However, the time span between CC
exposure and TF mRNA induction of 1 h points to a shorter in-
duction time than is needed for activation of TNF. It is, thus, more
likely that these processes are initiated in parallel in connection
to complement than that TNF plays a central role in the initial
TF induction by CC. The NLRP3 inflammasome has been linked
to CC-induced IL-1b secretion mediated by C5a (10). Further on,
NLRP3 has been linked to induction of TF-MP. However, our
investigation in whole blood using the specific NLRP3 inhibitor
MCC950, caspase-1 inhibitor VX-765, and pan-caspase inhibitor
Z-VAD-FMK did not provide evidence for its involvement in CC-
induced TF expression or downstream coagulation activation (data
not shown). Additionally, no induction of TF-MP by CC was
observed in our system. As regulation of TF has been shown to
occur mainly on the transcriptional level (37), our findings imply
that CC-induced generation of C5a activates the C5a–C5aR1 axis
to drive synthesis of TF mRNA, which has been shown to occur
both in monocytes (38) and in endothelial cells (39).
From the present and previous data, CC can be regarded as
participators in thromboinflammation with a strong dependency on
complement. Our investigation points to the monocytes as the only
leukocytes able to induce TF upon exposure to CC, as surface
expression on granulocytes and eosinophils was absent. CR3
expression is, in contrast, induced both on the monocytes and
granulocytes (10), and our explorations also revealed increased
granulocyte granularity upon CC exposure (data not shown). This
further points to the ability of CC to activate the granulocytes but
not induce surface expression of TF. Although there is agreement
regarding the capability of monocytes to express TF, the expres-
sion of TF on other cell types is debated (40–42). These dis-
crepancies in cellular sources could be related to the health status
of the donors as well as the type of stimuli (36, 42, 43). Platelets
contribute in the initial clot-formation process by binding to
damaged vascular endothelium (44), and connections between
platelets and monocyte TF are commonly accepted (45). We found
no direct effect of CC on platelet aggregation or in the induction
of PTF1.2 following CC exposure in platelet-containing plasma
(data not shown). The tiny induction of PTF1.2 following CC
exposure in PFP, which was still significantly inhibited by CTI,
suggests a small contribution of FXII in CC-induced coagulation.
This could also explain the ∼10% of PTF1.2 activity remaining
following complement inhibition. A limitation of the lepirudin
anticoagulant is the inhibition of thrombin, the major platelet
activator (46). However, because the platelets also contain com-
plement receptors (47), a complement-dependent coagulation ac-
tivation by the platelets could be possible. The presence of iC3b
in the outermost parts of the thrombus also opens a role for
complement–platelet interactions in thrombus growth, as previ-
ously described (22, 48).
CC are normally observed as imprints (CC clefts) in plaques
because of their dissolution when specimens are treated with
ethanol during regular immunohistochemical staining (31). CC
accumulation over time gives rise to cleft structures within ath-
erosclerotic plaques that are easily observed under the micro-
scope. However, upon plaque rupture, CC will be subjected to
blood flow and, therefore, more challenging to detect during
thrombus formation. CC can be observed using polarization
filter reflected light microscopy because of their high birefringence
















(30). The detection of complement products is also more efficient
in frozen samples, as used in this study. A recent paper suggests
that freezing biopsy specimens from atherosclerotic plaques may
produce birefringent structures in frozen section samples that do
not represent CC (49). An exclusion of such artifacts from the
present images is not possible, but still, several findings support
the birefringent structures being of CC origin: 1) the birefringent
structures were associated with activated complement, monocytes,
and TF; 2) monocytes or TF+ cells were adjacent to CC structures;
3) the shape of the birefringent structures resembled the square
CC made in vitro for the smaller structures, whereas the larger
needle-shaped or larger assemblies were similar to those seen in
atherosclerotic plaques; and 4) upon HES staining of stepwise
ethanol treatment, the birefringent structures disappeared, thereby
supporting that the structures contained cholesterol. Altogether,
these findings point to a CC nature of the birefringent structures.
Based on the efficiency of complement inhibition in reducing
CC-induced coagulation, targeting complement warrants further
exploration as a future treatment option for prevention of throm-
bosis. Currently, the complement C3 inhibitor CP40 is under
clinical development (50), whereas the C5 inhibitor eculizumab is
in clinical use for treatment of paroxysmal nocturnal hemoglo-
binuria (51). These patients often suffer from thromboembolism,
and targeted treatment of C5 has proven to reduce the thrombotic
events by 81% (51). In a preclinical porcine model of myocardial
infarction, C5 treatment also reduced the infarction size (52).
Targeting IL-1b has recently been proven to reduce the incidence
of thrombosis in patients with underlying atherosclerosis (53). Of
note, complement activation is an upstream event to the inflam-
matory cytokines, including IL-1b (10), and thus, targeting
complement could represent an alternative strategy. This might
also avoid a compromised immune activation upon infections, as
is the concern with anti–IL-1b therapy (53).
In conclusion, the current study reveals a role for CC in
thromboinflammation. CC possess a procoagulant feature de-
pendent on complement and monocytic TF, and following plaque
rupture, releasable CC might contribute to thrombosis. The use of
complement inhibitors targeting either C3, C5, or C5aR1 could be an
alternative clinical strategy for prophylactic treatment of atheroscle-
rotic plaques or after thrombosis and warrants further exploration.
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lesterol crystals induce complement-dependent inflammasome activation and
cytokine release. J. Immunol. 192: 2837–2845.
11. Niyonzima, N., B. Halvorsen, B. Sporsheim, P. Garred, P. Aukrust,
T. E. Mollnes, and T. Espevik. 2017. Complement activation by cholesterol
crystals triggers a subsequent cytokine response. Mol. Immunol. 84: 43–50.
12. Markiewski, M. M., B. Nilsson, K. N. Ekdahl, T. E. Mollnes, and J. D. Lambris.
2007. Complement and coagulation: strangers or partners in crime? Trends
Immunol. 28: 184–192.
13. Gravastrand, C., S. Hamad, H. Fure, B. Steinkjer, L. Ryan, J. Oberholzer,
J. D. Lambris, I. Lacı́k, T. E. Mollnes, T. Espevik, et al. 2017. Alginate
microbeads are coagulation compatible, while alginate microcapsules activate
coagulation secondary to complement or directly through FXII. Acta Biomater.
58: 158–167.
14. Landsem, A., H. Fure, D. Christiansen, E. W. Nielsen, B. Østerud, T. E. Mollnes,
and O. L. Brekke. 2015. The key roles of complement and tissue factor in
Escherichia coli-induced coagulation in human whole blood. Clin. Exp. Immu-
nol. 182: 81–89.
15. Langer, F., B. Spath, C. Fischer, M. Stolz, F. A. Ayuk, N. Kröger, C. Bokemeyer,
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Table 1. TF expression in whole blood at the transcription level (TF mRNA).  
 Baseline 60 min 120 min 240 min 
T0 (baseline) 1.0  0.0 - - - 
PBS/HSA - 29  7.1 213  96.5 351  185 
CC500 µg/mL - 295  77**** 490  202 131  80 
CC1000 µg/mL - 574  205**** 619  365 273  173 
CC2000 µg/mL - 674  231**** 429  244 131  80* 
E.coli (1x107 
particles/mL) 
- 1978  516**** 1356  333**** 419  111 
Glass - 91  13* 235  48 818  437 
TF mRNA RQT0 given as mean  SEM from all stimuli at T0, T60, T120 and T240. N=6. Significance levels compared to 






















Table 2. Coagulation activation measured as monocytic TF.  
 Baseline 60 min 120 min 240 min 
T0 (baseline) 0.10  0.10 - - - 
PBS/HSA - 0.2  0.1 0.7  0.5 5  1.2 
CC500 µg/mL - 4.6  1.0 14  2.9*** 18  2.7*** 
CC1000 µg/mL - 8.6  1.5* 19  2.9**** 20  2.9**** 
CC2000 µg/mL - 11  2.0*** 23  2.8**** 18  2.0*** 
E.coli (1x107 
particles/mL) 
- 43  4.5**** 76.1  2.8**** 73  2.6**** 
Glass - 0.3  0.2 5.3  1.9 20.4  6.0**** 
% TF positive monocytes given as mean  SEM from all stimuli at T0, T60, T120 and T240. N=6. Significance levels 




























Suppl. S1. Immunohistochemistry of frozen sections (4 µm) of human intracranial thrombi (A). 
CD68 (monocytes/macrophages). (B). Staining against CD61 (platelets). (C). Negative control. Scale 













Suppl. S2. Immunohistochemistry of frozen sections of human vulnerable plaque from a patient 
with an advanced carotid atherosclerosis explored with polarization filter reflected light 
microscopy. (A). Sections at 4x resolution showing HES staining with cholesterol crystals (CC) clefts 
and further immunohistochemical staining with the monocyte/macrophage marker CD68, endothelial 
marker CD34 and platelets marker CD61. Arrows are to corresponding areas in Fig. 7 showing 
CD14bright (yellow) monocytes and CD14low/TF+ (blue) monocytes respectively. Scale bar 200 µm. (B). 
HES stained area of the monocytes (yellow arrows) and the area corresponding to the TF positive 
staining (blue arrows). Inserts are showing the cell nucleus in specified areas within these regions.  
(C). CD14 staining showing CD14bright monocytes (yellow arrows) and CD14low monocytes (blue 
arrows) with cholesterol crystals (CC) structures in adjacent area. (D). TF staining showing TF+ 
leukocytes in area corresponding to the CD14low monocytes above. CC structures are found in adjacent 
area. (E). CD34 staining showing CD34+cells in the area corresponding to the CD14bright monocytes. 
B-E is taken by 10x (scale bar 100 µm) and 40x resolution for inserts (scale bar 30 µm).  
